Alprostadil Injection

1. This product is an intravenous alprostadil preparation with lipid microspheres as drug carriers. Due to the encapsulation of lipid microspheres, alprostadil is not easy to be inactivated, and has the targeted characteristics of being easily distributed to damaged blood vessels, thereby exerting the effects of this product in dilating blood vessels and inhibiting platelet aggregation. 2. In addition, this product also has the effects of stabilizing liver cell membranes and improving liver function.

Prostaglandin E1. Excipients: refined soybean oil, refined lecithin, concentrated glycerol, oleic acid, sodium hydroxide, water for injection.

1. Treat limb ulcers caused by chronic arterial occlusive disease (thromboangiitis obliterans, arteriosclerosis obliterans, etc.) and limb rest pain caused by microvascular circulatory disorders, and improve cardiovascular and cerebrovascular microcirculatory disorders. 2. Antithrombotic therapy after organ transplantation to inhibit thrombosis in the transplanted blood vessels. 3. Arterial duct-dependent congenital heart disease to relieve hypoxemia and maintain ductal blood flow to wait for surgical treatment. 4. For the adjuvant treatment of chronic hepatitis.

For adults, once a day, slowly inject 1-2 ml (alprostadil 5-10 mu g) + 10 ml normal saline (or 5% glucose) intravenously, or directly inject slowly into a small pot intravenously.

1. Shock: Shock may occur occasionally. Pay close attention to observation. If any abnormality is found, stop the drug immediately and take appropriate measures. 2. Injection site: Sometimes vascular pain, vasculitis, redness, and occasionally hardening and itching may occur. 3. Circulatory system: Sometimes symptoms such as aggravated heart failure, pulmonary edema, chest tightness, and decreased blood pressure may occur. Stop the drug immediately if they occur. In addition, facial flushing and palpitations may occur occasionally. 4. Digestive system: Sometimes diarrhea, abdominal distension, and discomfort may occur. Occasionally, abdominal pain, loss of appetite, vomiting, constipation, and elevated transaminase may occur. 5. Mental and nervous system: Sometimes dizziness, headache, fever, fatigue, and occasionally numbness may occur. 6. Blood system: Occasionally, eosinophilia and leukopenia may occur. 7. Others: Occasionally, decreased vision, swelling in the mouth, hair loss, pain in the limbs, edema, and urticaria may occur.

The following patients are contraindicated: 1. Patients with severe heart failure (heart failure). 2. Women who are pregnant or may become pregnant. 3. Patients with a history of allergic reaction to this preparation. 1. Patients with severe heart failure (heart failure). 2. Women who are pregnant or may become pregnant. 3. Patients with a history of allergic reaction to this preparation.

Precautions for children: The recommended infusion rate for children with congenital heart disease is 5ng/kg/min. Precautions for pregnancy and lactation: FDA pregnancy drug classification: No studies have been conducted on pregnant women, but no effects on the fetus have been seen in animal reproduction studies, and the therapeutic benefits of using this drug in pregnant women may outweigh its potential harms. Alternatively, this drug has not been tested on animals, and there have been no sufficiently rigorous controlled studies on pregnant women. Women who are pregnant or may become pregnant are prohibited from using this product. Precautions for the elderly: No special instructions, please follow the doctor's advice.

Avoid mixing with plasma expanders (dextran, gelatin preparations, etc.).

Keep away from light, store at 0-5℃, avoid freezing.

1 ml: 5ug

12 months.

Harbin Pharmaceutical Group Bioengineering Co., Ltd.

• Founded in:

  1995-02-20

• Address:

  No. 99, Zhuhai Road, Limin Development Zone, Hulan District, Harbin

• Tax NO.:

  91230111128024298B

• Registered Funds:

  186.0655 million yuan

• Website:

  Log in to view

• Email:

  Log in to view